Evidence map›Paper›PMID 28926934›Full record

ArticleInternational journal of molecular sciences2017

The Beneficial Effects of Allicin in Chronic Kidney Disease Are Comparable to Losartan.

Ehécatl Miguel Ángel García Trejo, Abraham Said Arellano Buendía, Omegar Sánchez Reyes, Fernando Enrique García Arroyo, Raúl Arguello García, María Lilia Loredo Mendoza, Edilia Tapia, Laura Gabriela Sánchez Lozada, Horacio Osorio Alonso

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
7.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Sirtuins and Renal Oxidative Stress.Antioxidants (Basel, Switzerland) · 2021
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ehécatl Miguel Ángel García TrejoRenal Physiopathology Laboratory, Depterment of Nephrology, Instituto Nacional de Cardiología "Ignacio Chávez", Mexico City 14080, Mexico. dr.ehecatl@hotmail.com.
Abraham Said Arellano BuendíaRenal Physiopathology Laboratory, Depterment of Nephrology, Instituto Nacional de Cardiología "Ignacio Chávez", Mexico City 14080, Mexico. neoabraham_7@hotmail.com.
Omegar Sánchez ReyesRenal Physiopathology Laboratory, Depterment of Nephrology, Instituto Nacional de Cardiología "Ignacio Chávez", Mexico City 14080, Mexico. tuzome_sanrey23@hotmail.com.
Fernando Enrique García ArroyoRenal Physiopathology Laboratory, Depterment of Nephrology, Instituto Nacional de Cardiología "Ignacio Chávez", Mexico City 14080, Mexico. jonibertojr@hotmail.com.
Raúl Arguello GarcíaDepartamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados-IPN, Mexico City 07360, Mexico. raularguellogarcia@yahoo.com.
María Lilia Loredo MendozaHistopathology Laboratory, Research Subdivision, School of Medicine, Universidad Panamericana, Donatello 43, Mexico City 03910, Mexico. lloredo@up.edu.mx.
Edilia TapiaRenal Physiopathology Laboratory, Depterment of Nephrology, Instituto Nacional de Cardiología "Ignacio Chávez", Mexico City 14080, Mexico. ediliatapia@hotmail.com.
Laura Gabriela Sánchez LozadaRenal Physiopathology Laboratory, Depterment of Nephrology, Instituto Nacional de Cardiología "Ignacio Chávez", Mexico City 14080, Mexico. lgsanchezlozada@gmail.com.
Horacio Osorio AlonsoRenal Physiopathology Laboratory, Depterment of Nephrology, Instituto Nacional de Cardiología "Ignacio Chávez", Mexico City 14080, Mexico. horacio.osorio@cardiologia.org.mx.
Instituto Nacional de Cardiología · MXInstituto Politécnico Nacional · MXUniversidad Panamericana · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies suggest that allicin may play a role in chronic kidney disease (CKD), reducing hypertension and oxidative stress and improving renal dysfunction. In the present study, CKD was induced by 5/6 nephrectomy and the animals were divided into four treatment groups as follows: control (C), CKD, CKD+allicin (40 mg/kg pathway oral) (CKDA), and CKD+Losartan (20 mg/kg) (CKDL). After CKD induction, the rats developed hypertension from week 3 to the end of the study. This was associated with increased creatinine and blood urea nitrogen (BUN) levels in serum, increased albuminuria, increased urinary excretion of

Indexed as

AcetylglucosaminidaseAnimalsAntihypertensive AgentsAntioxidantsCreatinineDisulfidesKelch-Like ECH-Associated Protein 1KidneyLosartanMaleMembrane ProteinsNitric Oxide Synthase Type IIIOxidative StressRatsRats, WistarReceptors, AngiotensinAcetylglucosaminidaseallicinAntihypertensive AgentsAntioxidantsCreatinineDisulfidesKEAP1 protein, ratKelch-Like ECH-Associated Protein 1Kirrel1 protein, ratLosartanMembrane ProteinsNitric Oxide Synthase Type IIIReceptors, AngiotensinSulfinic AcidsUreaallicinchronic kidney diseasehypertensionlosartanoxidative stress

Identifiers

PMID28926934
PMCPMC5618629
OpenAlexW2755138568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.